Hematopoietic stem cell transplantation for acute leukemia in the era of targeted therapies and immunotherapy
-
摘要: 目前造血干细胞移植已成为急性白血病治疗中不可或缺的组成部分。虽然过去20年来靶向治疗及免疫治疗迅速发展，提高了急性白血病的疗效，但造血干细胞移植的治疗地位依然不可取代。本文介绍了当前造血干细胞移植在急性白血病治疗中的作用，及靶向治疗与免疫治疗与造血干细胞移植结合对急性白血病患者疗效的改善。
-
关键词:
- 自体造血干细胞移植 /
- 异基因造血干细胞移植 /
- 靶向治疗 /
- 免疫治疗
Abstract: Hematopoietic stem cell transplantation(HSCT) is an integral therapy in the treatment of acute leukemia. In the last 2 decades, novel targeted therapies and immunotherapies have been dramatically developed. But HSCT remains to be prominent in the treatment paradigms of acute leukemias. In this review, we described the current role of autologous and allogeneic HSCT in the treatment of acute leukemia, and discussed the incorporation of novel targeted therapies and immunotherapies with HSCT to improve the outcome of patients with acute leukemias. -
-
[1] Nagler A, Labopin M, Houhou M, et al. Outcome of haploidentical versus matched sibling donors in hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation[J]. J Hematol Onco, 2021, 14(1): 53. doi: 10.1186/s13045-021-01065-7
[2] Salvatore D, Labopin M, Ruggeri A, et al. Outcomes of hematopoietic stem cell transplantation from unmanipulated haploidentical versus matched sibling donor in patients with acute myeloid leukemia in first complete remission with intermediate or high-risk cytogenetics: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation[J]. Haematologica, 2018, 103(8): 1317-1328. doi: 10.3324/haematol.2018.189258
[3] Sanz J, Galimard JE, Labopin M, et al. Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia: a comparative study of the ALWP EBMT[J]. J Hematol Oncol, 2020, 13(1): 46. doi: 10.1186/s13045-020-00882-6
[4] Sanz J, Galimard JE, Labopin M, et al. Post-transplant cyclophosphamide containing regimens after matched sibling, matched unrelated and haploidentical donor transplants in patients with acute lymphoblastic leukemia in first complete remission, a comparative study of the ALWP of the EBMT[J]. J Hematol Oncol, 2021, 14(1): 84. doi: 10.1186/s13045-021-01094-2
[5] Döhner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN[J]. Blood, 2022, 140(12): 1345-1377. doi: 10.1182/blood.2022016867
[6] Pollyea DA, Bixby D, Perl A, et al. NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021[J]. J Nat Compr Cancer Netw, 2021 19(1): 16-27. doi: 10.6004/jnccn.2021.0002
[7] Cornelissen JJ, Gratwohl A, Schlenk RF, et al. The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach[J]. Nat Rev Clin Oncol, 2012, 9(10): 579-590. doi: 10.1038/nrclinonc.2012.150
[8] Yao J, Zhang G, Liang C, et al. Combination of cytogenetic classification and MRD status correlates with outcome of autologous versus allogeneic stem cell transplantation in adults with primary acute myeloid leukemia in first remission[J]. Leuk Res, 2017, 55: 97-104. doi: 10.1016/j.leukres.2017.01.026
[9] DiNardo CD, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia[J]. Blood, 2019, 133(1): 7-17. doi: 10.1182/blood-2018-08-868752
[10] DiNardo CD, Lachowiez CA, Takahashi K, et al. Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia[J]. J Clin Oncol, 2021, 39(25): 2768-7278. doi: 10.1200/JCO.20.03736
[11] Cortes JE, Lin TL, Asubonteng K, et al. Efficacy and safety of CPX-351 versus 7+3 chemotherapy by European LeukemiaNet 2017 risk subgroups in older adults with newly diagnosed, high-risk/secondary AML: post hoc analysis of a randomized, phase 3 trial[J]. J Hematol Oncol, 2022, 15(1): 155. doi: 10.1186/s13045-022-01361-w
[12] Castaigne S, Pautas C, Terré C, et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia(ALFA-0701): a randomised, open-label, phase 3 study[J]. Lancet, 2012, 379(9825): 1508-1516. doi: 10.1016/S0140-6736(12)60485-1
[13] Pollard JA, Guest E, Alonzo TA, et al. Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric KMT2A-Rearranged AML: Results From the Phase Ⅲ Children's Oncology Group Trial AAML0531[J]. J Clin Oncol, 2021, 39(28): 3149-3160. doi: 10.1200/JCO.20.03048
[14] Lambert J, Pautas C, Terré C, et al. Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase Ⅲ ALFA-0701 trial[J]. Haematologica, 2019, 104(1): 113-119. doi: 10.3324/haematol.2018.188888
[15] Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation[J]. N Engl J Med, 2017, 377(5): 454-464. doi: 10.1056/NEJMoa1614359
[16] Perl AE, Martinelli G, Cortes JE, et al. Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML[J]. N Engl J Med, 2019, 381(18): 1728-1740. doi: 10.1056/NEJMoa1902688
[17] Perl AE, Larson RA, Podoltsev NA, et al. Outcomes in Patients with FLT3-Mutated Relapsed/Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy[J]. Transplant Cell Ther, 2023, 29(4): 265.e1-65.e10. doi: 10.1016/j.jtct.2022.12.006
[18] DiNardo CD, Stein EM, de Botton S, et al. Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML[J]. N Engl J Med, 2018, 378(25): 2386-2398. doi: 10.1056/NEJMoa1716984
[19] Montesinos P, Recher C, Vives S, et al. Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia[J]. N Engl J Med, 2022, 386(16): 1519-1531. doi: 10.1056/NEJMoa2117344
[20] Yin J, Zhu F, Zhang ZB, et al. Rapid and deep response to avapritinib in heavily treated acute myeloid leukemia with t(8;21) and KIT mutation[J]. Ann Hematol, 2022, 101(10): 2347-2350. doi: 10.1007/s00277-022-04897-6
[21] Xuan L, Wang Y, Yang K, et al. Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FLT3-ITD acute myeloid leukaemia: long-term follow-up of an open-label, multicentre, randomised, phase 3 trial[J]. Lancet Haematol, 2023, 10(8): e600-e611. doi: 10.1016/S2352-3026(23)00117-5
[22] Terao T, Matsuoka KI, Ueda H, et al. Early initiation of low-dose gilteritinib maintenance improves posttransplant outcomes in patients with R/R FLT3mut AML[J]. Blood Adv, 2023, 7(5): 681-686. doi: 10.1182/bloodadvances.2022008991
[23] Kent A, Schwartz M, McMahon C, et al. Venetoclax is safe and tolerable as post-transplant maintenance therapy for AML patients at high risk for relapse[J]. Bone Marrow Transplant, 2023 Apr 25. doi: 10.1038/s41409-023-01987-5.Onlineaheadofprint.
[24] Wei Y, Xiong X, Li X, et al. Low-dose decitabine plus venetoclax is safe and effective as post-transplant maintenance therapy for high-risk acute myeloid leukemia and myelodysplastic syndrome[J]. Cancer Sci, 2021, 112(9): 3636-3644. doi: 10.1111/cas.15048
[25] Fathi AT, Kim HT, Soiffer RJ, et al. Enasidenib as maintenance following allogeneic hematopoietic cell transplantation for IDH2-mutated myeloid malignancies[J]. Blood Adv, 2022, 6(22): 5857-5865. doi: 10.1182/bloodadvances.2022008632
[26] Gao F, Gao Y, Luo Y, et al. Venetoclax plus hypomethylating agent for the salvage treatment of relapsing myeloid malignancies after hematopoietic stem cell transplantation: A multicenter retrospective study on behalf of the Zhejiang Cooperative Group for Blood and Marrow Transplantation[J]. Am J Hematol, 2022, 97(2): E44-E47.
[27] Kong J, Zheng FM, Wang ZD, et al. Avapritinib is effective for treatment of minimal residual disease in acute myeloid leukemia with t(8;21) and kit mutation failing to immunotherapy after allogeneic hematopoietic stem cell transplantation[J]. Bone Marrow Transplant, 2023, 58(7): 777-783. doi: 10.1038/s41409-023-01973-x
[28] Cui Q, Qian C, Xu N, et al. CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation[J]. J Hematol Oncol, 2021, 14(1): 82. doi: 10.1186/s13045-021-01092-4
[29] Breems DA, Löwenberg B. Acute myeloid leukemia and the position of autologous stem cell transplantation[J]. Semin Hematol, 2007, 44(4): 259-266. doi: 10.1053/j.seminhematol.2007.08.002
[30] Yu S, Lin T, Nie D, et al. Dynamic assessment of measurable residual disease in favorable-risk acute myeloid leukemia in first remission, treatment, and outcomes[J]. Blood Cancer J, 2021, 11(12): 195. doi: 10.1038/s41408-021-00591-4
[31] Yu S, Fan Z, Ma L, et al. Association Between Measurable Residual Disease in Patients With Intermediate-Risk Acute Myeloid Leukemia and First Remission, Treatment, and Outcomes[J]. JAMA Netw Open, 2021, 4(7): e2115991. doi: 10.1001/jamanetworkopen.2021.15991
[32] Brown PA, Shah B, Advani A, et al. Acute Lymphoblastic Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology[J]. J Natl Compr Cancer Netw, 2021, 19(9): 1079-1109. doi: 10.6004/jnccn.2021.0042
[33] Nagler A, Labopin M, Swoboda R, et al. Haploidentical Versus Matched Sibling Donor Hematopoietic Stem Cell Transplantation for Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia: A Study From the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation[J]. Hemasphere, 2022, 6(11): e790. doi: 10.1097/HS9.0000000000000790
[34] Zhang XH, Chen J, Han MZ, et al. The consensus from The Chinese Society of Hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update[J]. J Hematol Oncol, 2021, 14(1): 145. doi: 10.1186/s13045-021-01159-2
[35] Lazaryan A, Dolan M, Zhang MJ, et al. Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research[J]. Haematologica, 2021, 106(8): 2295-2296. doi: 10.3324/haematol.2021.279046
[36] Gökbuget N, Kneba M, Raff T, et al. Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies[J]. Blood, 2012, 120(9): 1868-1876. doi: 10.1182/blood-2011-09-377713
[37] Gökbuget N, Dombret H, Giebel S, et al. Minimal residual disease level predicts outcome in adults with Ph-negative B-precursor acute lymphoblastic leukemia[J]. Hematology, 2019, 24(1): 337-348. doi: 10.1080/16078454.2019.1567654
[38] Fu W, Huang A, Lu G, et al. Value of pre-transplant consolidation chemotherapy in adults with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation without minimal residual disease in first complete remission[J]. Leuk Lymphoma, 2021, 62(4): 952-959. doi: 10.1080/10428194.2020.1845340
[39] Liu C, Zhang X, Mao L, et al. Olverembatinib in relapsed Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia: a study of 5 cases[J]. Leuk Lymphoma, 2023, 64(6): 1208-1211. doi: 10.1080/10428194.2023.2197534
[40] Ribera JM, García-Calduch O, Ribera J, et al. Ponatinib, chemotherapy, and transplant in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia[J]. Blood Adv, 2022, 6(18): 5395-5402. doi: 10.1182/bloodadvances.2022007764
[41] Jabbour E, Haddad FG, Short NJ, et al. Treatment of Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia-From Intensive Chemotherapy Combinations to Chemotherapy-Free Regimens: A Review[J]. JAMA Oncol, 2022, 8(9): 1340-1348. doi: 10.1001/jamaoncol.2022.2398
[42] Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia[J]. N Engl J Med, 2018, 378(5): 439-448. doi: 10.1056/NEJMoa1709866
[43] Laetsch TW, Maude SL, Rives S, et al. Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial[J]. J Clin Oncol, 2023, 41(9): 1664-1669. doi: 10.1200/JCO.22.00642
[44] Shah BD, Ghobadi A, Oluwole OO, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study[J]. Lancet, 2021, 398(10299): 491-502. doi: 10.1016/S0140-6736(21)01222-8
[45] Chen W, Ma Y, Shen Z, et al. Humanized Anti-CD19 CAR-T Cell Therapy and Sequential Allogeneic Hematopoietic Stem Cell Transplantation Achieved Long-Term Survival in Refractory and Relapsed B Lymphocytic Leukemia: A Retrospective Study of CAR-T Cell Therapy[J]. Front Immunol, 2021, 12: 755549. doi: 10.3389/fimmu.2021.755549
[46] Kantarjian H, Stein A, Gökbuget N, et al. Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia[J]. N Engl J Med, 2017, 376(9): 836-847. doi: 10.1056/NEJMoa1609783
[47] Gökbuget N, Dombret H, Bonifacio M, et al. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia[J]. Blood, 2018, 131(14): 1522-1531. doi: 10.1182/blood-2017-08-798322
[48] Jabbour E, Short NJ, Jain N, et al. Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial[J]. Lancet Haematol, 2023, 10(1): e24-e34. doi: 10.1016/S2352-3026(22)00319-2
[49] Kantarjian HM, DeAngelo DJ, Stelljes M, et al. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia[J]. N Engl J Med, 2016, 375(8): 740-753. doi: 10.1056/NEJMoa1509277
[50] Jabbour E, Sasaki K, Short NJ, et al. Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia[J]. Cancer, 2021, 127(12): 2025-2038. doi: 10.1002/cncr.33469
[51] Lv M, Liu L, He Y, et al. Outcomes of allogeneic or autologous stem cell transplantation followed by maintenance chemotherapy in adult patient with B-ALL in CR1 with no detectable minimal residual disease[J]. Br J Haematol, 2023, 202(2): 369-378. doi: 10.1111/bjh.18846
[52] Warraich Z, Tenneti P, Thai T, et al. Relapse Prevention with Tyrosine Kinase Inhibitors after Allogeneic Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblast Leukemia: A Systematic Review[J]. Biol Blood Marrow Transplant, 2020, 26(3): e55-e64. doi: 10.1016/j.bbmt.2019.09.022
[53] Gaballa MR, Banerjee P, Milton DR, et al. Blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemia[J]. Blood, 2022, 139(12): 1908-1919. doi: 10.1182/blood.2021013290
[54] Zhang C, Wang XQ, Zhang RL, et al. Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant[J]. Leukemia, 2021, 35(6): 1563-1570. doi: 10.1038/s41375-020-01056-6
[55] Lu P, Liu Y, Yang J, et al. Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL/LBL: first-in-human phase 1 clinical trial[J]. Blood, 2022, 140(4): 321-334.
[56] Zhang M, Chen D, Fu X, et al. Autologous Nanobody-Derived Fratricide-Resistant CD7-CAR T-cell Therapy for Patients with Relapsed and Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma[J]. Clin Cancer Res, 2022, 28(13): 2830-2843. doi: 10.1158/1078-0432.CCR-21-4097
[57] Izumi A, Tachibana T, Ando T, et al. A case series of patients treated with inotuzumab ozogamicin for acute lymphoblastic leukemia relapsed after allogeneic hematopoietic cell transplantation[J]. Int J Hematol, 2022, 115(1): 69-76. doi: 10.1007/s12185-021-03217-4
[58] Filippini Velázquez G, Labopin M, Tischer J, et al. Second haploidentical stem cell transplantation(HAPLO-SCT2) after relapse from a first HAPLO-SCT in acute leukaemia-a study on behalf of the Acute Leukaemia Working Party(ALWP)of the European Society for Blood and Marrow Transplantation(EBMT)[J]. Bone Marrow Transplant, 2023 May 9. doi: 10.1038/s41409-023-01985-7.Onlineaheadofprint.
[59] Lv M, Liu L, He Y, et al. Outcomes of allogeneic or autologous stem cell transplantation followed by maintenance chemotherapy in adult patient with B-ALL in CR1 with no detectable minimal residual disease[J]. Br J Haematol, 2023, 202(2): 369-378. doi: 10.1111/bjh.18846
[60] Ding Z, Han MZ, Chen SL, et al. Outcomes of Adults with Acute Lymphoblastic Leukemia After Autologous Hematopoietic Stem Cell Transplantation and the Significance of Pretransplantation Minimal Residual Disease: Analysis from a Single Center of China[J]. Chin Med J(Engl), 2015, 128(15): 2065-2071.
[61] Lyu M, Jiang E, He Y, et al. Comparison of autologous and allogeneic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia[J]. Hematology, 2021, 26(1): 65-74. doi: 10.1080/16078454.2020.1868783
-
计量
- 文章访问数: 956
- PDF下载数: 448
- 施引文献: 0
下载: